000			02096 a2200601 4500
005			20250517103042.0
264		0	_c20180105
008			201801s 0 0 eng d
022			_a1878-0210
024	7		_a10.1016/j.pcd.2016.06.001 _2doi
040			_aNLM _beng _cNLM
100	1		_aPrasanna Kumar, K M
245	0	0	_aEffectiveness of vildagliptin versus other oral antidiabetes drugs as add-on to sulphonylurea monotherapy: Post hoc analysis from the EDGE study. _h[electronic resource]
260			_bPrimary care diabetes _c12 2016
300			_a452-458 p. _bdigital
500			_aPublication Type: Comparative Study; Journal Article; Multicenter Study; Observational Study
650	0	4	_aAdamantane _xadministration & dosage
650	0	4	_aAdministration, Oral
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aBiomarkers _xblood
650	0	4	_aBlood Glucose _xdrug effects
650	0	4	_aDiabetes Mellitus, Type 2 _xblood
650	0	4	_aDipeptidyl-Peptidase IV Inhibitors _xadministration & dosage
650	0	4	_aDrug Therapy, Combination
650	0	4	_aFemale
650	0	4	_aGlycated Hemoglobin _xmetabolism
650	0	4	_aHumans
650	0	4	_aHyperglycemia _xchemically induced
650	0	4	_aHypoglycemic Agents _xadministration & dosage
650	0	4	_aIndia
650	0	4	_aLogistic Models
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aMultivariate Analysis
650	0	4	_aNitriles _xadministration & dosage
650	0	4	_aOdds Ratio
650	0	4	_aProspective Studies
650	0	4	_aPyrrolidines _xadministration & dosage
650	0	4	_aRisk Factors
650	0	4	_aSulfonylurea Compounds _xadministration & dosage
650	0	4	_aTime Factors
650	0	4	_aTreatment Outcome
650	0	4	_aVildagliptin
650	0	4	_aWeight Gain _xdrug effects
700	1		_aPhadke, U
700	1		_aBrath, H
700	1		_aGawai, A
700	1		_aPaldánius, P M
700	1		_aMathieu, C
773	0		_tPrimary care diabetes _gvol. 10 _gno. 6 _gp. 452-458
856	4	0	_uhttps://doi.org/10.1016/j.pcd.2016.06.001 _zAvailable from publisher's website
999			_c26169951 _d26169951